Base Metals Investing Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
Base Metals Investing Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Base Metals Investing Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
Base Metals Investing Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Base Metals Investing Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Base Metals Investing Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
